Baseline demographics and clinical characteristics of patients with IMID
| Overall | Non-RTX | RTX | |
| N | 66 | 33 | 33 |
| Age, years, mean (SD) | 63.3 (14.0) | 63.9 (14.1) | 62.8 (14.0) |
| Gender, N (%) | |||
| Male | 26 (39.4) | 13 (39.4) | 13 (39.4) |
| Female | 40 (60.6) | 20 (60.6) | 20 (60.6) |
| BMI, mean (SD) | 26.4 (6.6) | 26.1 (4.1) | 26.7 (8.0) |
| Diagnosis, N (%) | |||
| Rheumatoid arthritis | 30 (45.5) | 17 (51.5) | 13 (39.4) |
| Spondyloarthritis* | 4 (6.1) | 4 (12.1) | 0 |
| Connective tissue disease | 13 (19.7) | 5 (15.2) | 8 (24.2) |
| Others | 5 (7.6) | 3 (9.1) | 2 (6.1) |
| Systemic vasculitis | 14 (21.2) | 4 (12.1) | 10 (30.3) |
| Comorbidities, N (%) | |||
| Diabetes | 9 (13.6) | 4 (12.1) | 5 (15.2) |
| Hypertension | 25 (37.9) | 16 (48.5) | 9 (27.3) |
| Ischaemic heart disease | 4 (6.1) | 2 (6.1) | 2 (6.1) |
| Cancer | 6 (9.1) | 3 (9.1) | 3 (9.1) |
| Lung disease | 11 (16.7) | 3 (9.1) | 8 (24.2) |
| Treatment, N (%) | |||
| Tumour necrosis factor-alpha | 5 (7.6) | 5 (15.2) | 0 |
| Interleukin-17 | 2 (3.0) | 2 (6.1) | 0 |
| Interleukin −6 | 1 (1.5) | 1 (3.0) | 0 |
| Interleukin −1 | 1 (1.5) | 1 (3.0) | 0 |
| CD-20 | 33 (50.0) | 0 | 33 (100.0) |
| CD80/86 | 5 (7.6) | 3 (9.1) | 2 (6.1) |
| Integrin α4β7 | 1 (1.5) | 1 (3.0) | 0 |
| JAKi | 7 (21.2) | 7 (21.2) | 0 |
| csDMARD | 22 (33.3) | 17 (51.5) | 5 (15.2) |
| Glucocorticoids | 30 (45.5) | 14 (42.4) | 16 (48.5) |
| Vaccination, N (%) | |||
| Primary mRNA vaccine | 58 (87.9) | 29 (87.9) | 29 (87.9) |
| Primary vector vaccine | 8 (12.1) | 4 (12.1) | 4 (12.1) |
| Timing, median (IQR) | |||
| Days to second vaccination | 42 (22.5–42) | 41.5 (23–42) | 42 (22–42) |
| Days to third vaccination after second vaccination | 83 (55–112) | 93 (64–128) | 69 (47–95) |
| Days to sampling after third vaccination | 20 (15.5–28) | 20.5 (15–28) | 20 (17–27) |
*Including psoriatic arthritis.
BMI, body mass index; csDMARD, conventional synthetic disease modifying anti-rheumatic drugs; IMID, immune-mediated inflammatory disease; JAKi, Janus kinase inhibitors; RTX, rituximab.